Oncolytics Biotech’s (ONCY) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research report report published on Thursday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

Oncolytics Biotech Stock Down 3.0 %

Oncolytics Biotech stock opened at $0.98 on Thursday. Oncolytics Biotech has a one year low of $0.84 and a one year high of $1.75. The stock’s 50 day moving average is $1.09 and its 200 day moving average is $1.06.

Institutional Investors Weigh In On Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC purchased a new position in Oncolytics Biotech Inc. (NASDAQ:ONCY) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.